Media & press

Research presented at Digestive Disease Week 2026 strengthens the evidence base for precision obesity medicine, demonstrating its utility across both surgical and pharmacological treatments.

A national Phenomix Sciences survey of medication-experienced patients finds treatment discussions remain heavily centered on GLP-1s - but when patients are informed about additional options, they show greater openness to personalized care approaches.

Phenomix CEO Mark Bagnall discusses the reasons for GLP-1 failure and why it’s common for patients to stop taking the medication.

National survey shows patient expectations and perceptions of GLP-1s are evolving, and clearer education is shaping obesity treatment decisions.

Drugs like Wegovy and Zepbound have been hailed as miracle treatments. But one in 10 people are what scientists call “non-responders.”

In conjunction with Obesity Care Week, a national survey from Phenomix Sciences among medication-experienced patients found that GLP-1 outcomes, tolerability, and downstream care needs vary widely, reinforcing the need for more individualized obesity care.

A genetic risk score (GRS) predicted the risk emotional hunger (EH) in people with obesity and may enable testing of potential therapies.

Findings presented at the 2026 Pacific Symposium on Biocomputing demonstrate feasibility of using genetic and behavioral data to assess Emotional Hunger risk in obesity.

Studies presented at Obesity Week 2025 validate the test’s ability to predict weight-loss response to GLP-1 drugs like semaglutide, including in diverse patient populations and post-bariatric surgery patients.

Scientists look to genetics to explain why GLP-1 drugs work for some people but not for others

How genetic insights are reshaping weight loss strategies—moving beyond trial-and-error toward precision-guided interventions.

Clinical trials show people with different “genetic scores” lose more weight on specific drugs